Empowered Patient Podcast

Sanjeev Redkar, Co-Founder, Executive Director, and President of Apollomics, focuses on difficult-to-treat cancers, such as lung cancer, brain cancer, and leukemias, not served by immune checkpoint inhibitors. Their approach targets the thematic pathway in cancer cells responsible for their growth and proliferation. In their drug development, AI and data analysis drive precision-targeted therapies based on tumor molecular profiling. They are developing the drugs Vebreltinib and Uproleselan, which can be used as standalone treatments or in combination with other therapies to treat rare cancers. Sanjeev explains, "There's a pathway that is very important for the growth of cancer cells. This is proliferation, motility, migration, and invasion of cancer cells, and that's the thematic pathway. This is an important receptor, which is upstream in cell signaling of these cancer cells. This is when these pathways work well, these cells grow as normal homeostasis, normal growth of cells. When this pathway is disrupted